16 Jul Globus Medical Announces Completion of 20,000 Procedures Utilizing ExcelsiusGPS®
Globus Medical Announces Completion of 20,000 Procedures Utilizing ExcelsiusGPS®
AUDUBON, Pa., July 15, 2021 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that over 20,000 spine procedures have been performed utilizing the ExcelsiusGPS® Robotic Navigation system.
“The ExcelsiusGPS® platform is one of the most intuitive systems I have ever used. It was easy to learn and adapt into my operating room,” said Dr. Roland Kent, Orthopedic Spine Surgeon at Northwest Specialty Hospital in Post Falls, ID, who has performed over 300 procedures with ExcelsiusGPS®. “I have experienced significant decreases in our operative times, whether it be a single position lateral, a simple TLIF or a T10-to-pelvis deformity correction. I use ExcelsiusGPS® for almost every case I do.”
The number of cases that incorporate the ExcelsiusGPS® platform is at an all-time high. Specifically developed to overcome the limitations of minimally invasive surgery, ExcelsiusGPS® removes multiple stress factors and helps to maintain navigation integrity, allowing the surgeons to focus on patient care. ExcelsiusGPS® combines streamlined preoperative or intraoperative planning with fully integrated robotic trajectory alignment for a broad spectrum of spine applications. The robotic platform has been shown to help increase accuracy, reduce radiation, and generate time savings compared to conventional spine procedures.1
“At Globus, our mission is to improve patient care by developing game changing technology. We firmly believe commercial success is a product of clinical success,” said Mir Hussain, Director of Field Applications for Globus Medical’s Imaging, Navigation, Robotics Division. “It is both humbling and exciting to be part of the team that developed and launched this technology almost 4 years ago, and now it is being utilized in over 20,000 procedures around the world!”
About ExcelsiusGPS® Spine Solutions
ExcelsiusGPS® is the revolutionary robotic navigation platform that offers a comprehensive approach to spine procedures, from start-to-finish. The platform’s multifunctionality, imaging versatility and unique real-time information enable accurate trajectory alignment with integrated navigation for placing screws, for navigated disc preparation, and for placing interbody implants. ExcelsiusGPS® is the only robotic navigation system that was built from the ground up to comprehensively combine these advanced technologies. The system works with any Preoperative CT, Intraoperative CT, and Intraoperative Fluoroscopy. ExcelsiusGPS® is the only Robotic Navigation Platform that addresses the gaps of standard navigation and current robotic technologies. These features include an actively navigated end effector, patient movement tracking, force/deflection sensing, and DRB disruption monitoring. These features combine to provide safety redundancies throughout the procedure in order to maintain navigational integrity.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Contact:
Brian Kearns
Senior Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com
SOURCE: Globe Newswire, 15th July 2021